Periodontitis Stage III, Probiotic
Conditions
Keywords
Microbiology, Periodontitis, Probiotics, Cytokines
Brief summary
Aims: The use of oral probiotics as an adjunct to the treatment of periodontal diseases is known to be beneficial in antagonizing pathogenic microflora and regulating the host immune response. The aim of this clinical study was to evaluate the clinical, microbiologic and biochemical effect of Streptococcus salivarius (S. salivarius) K12 probiotic tablet as an adjunct to scaling and root planing (SRP) treatment in stage 3 periodontitis patients. Methods: The study included 30 systemically healthy stage 3 periodontitis patients. After non-surgical periodontal treatment, participants were randomly assigned to the test (SRP+Probiotic, n=15) or control (SRP, n=15) group. Patients in the test group used probiotic tablets once daily for 30 days. Clinical (Plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL)), microbiological (Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Prevotella intermedia, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum) and biochemical (IL-6, IL-8, IL-10) measurements were performed at baseline (before SRP), 30. and 90th days. Data were analyzed statistically. Keywords: Microbiology, Periodontitis, Probiotics, Cytokines
Interventions
OTHERProbiotic Agent
Patients in the test group were instructed to take one tablet immediately after tooth brushing (before bedtime) once daily for 30 consecutive days. Probiotic was administered in tablets containing 1x109 cfu/g S. salivarius K12.
Patients in the control group received non-surgical periodontal treatment only.
Sponsors
AYŞENUR ŞAHİN
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female aged 18-60 years, * No systemic disease, * No periodontal treatment in the last 6 months, * No antibiotic therapy in the last 6 months, * Diagnosed with stage 3 periodontitis according to the 2017 periodontal disease classification
Exclusion criteria
* Periodontal treatment within sixteen months, * Smoking, * Patients with systemic health problems such as diabetes, rheumatoid arthritis, neurological diseases, lung and kidney diseases, * Pregnancy or lactation, * Acute oral lesions or necrotizing ulcerative periodontitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Porphyromonas gingivalis at 3 months | From enrollment to the end of treatment at 12 weeks |
Countries
Turkey (Türkiye)
Outcome results
None listed